Anika Therapeutics Inc (ANIK) : Kalos Management reduced its stake in Anika Therapeutics Inc by 53.16% during the most recent quarter end. The investment management company now holds a total of 9,018 shares of Anika Therapeutics Inc which is valued at $433,766 after selling 10,236 shares in Anika Therapeutics Inc , the firm said in a disclosure report filed with the SEC on Aug 1, 2016.Anika Therapeutics Inc makes up approximately 0.33% of Kalos Management’s portfolio.
Other Hedge Funds, Including , California State Teachers Retirement System reduced its stake in ANIK by selling 1,461 shares or 4.71% in the most recent quarter. The Hedge Fund company now holds 29,554 shares of ANIK which is valued at $1,421,547.American Century Companies Inc reduced its stake in ANIK by selling 18,688 shares or 34.73% in the most recent quarter. The Hedge Fund company now holds 35,125 shares of ANIK which is valued at $1,846,873. Msi Financial Services Inc sold out all of its stake in ANIK during the most recent quarter. The investment firm sold 1,373 shares of ANIK which is valued $72,192.Acadian Asset Management reduced its stake in ANIK by selling 30,051 shares or 17.29% in the most recent quarter. The Hedge Fund company now holds 143,720 shares of ANIK which is valued at $7,483,500. Anika Therapeutics Inc makes up approx 0.04% of Acadian Asset Management’s portfolio.
Anika Therapeutics Inc opened for trading at $47.96 and hit $48.94 on the upside on Thursday, eventually ending the session at $48.11, with a gain of 0.02% or 0.01 points. The heightened volatility saw the trading volume jump to 1,18,846 shares. Company has a market cap of $689 M.
On the company’s financial health, Anika Therapeutics Inc reported $0.57 EPS for the quarter, beating the analyst consensus estimate by $ 0.13 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $0.44. The company had revenue of $26.60 million for the quarter, compared to analysts expectations of $24.73 million. The company’s revenue was up 16.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.51 EPS.
Many Wall Street Analysts have commented on Anika Therapeutics Inc. Singular Research Upgraded Anika Therapeutics Inc on May 9, 2016 to ” Buy”, Price Target of the shares are set at $60.
Anika Therapeutics Inc. develops manufactures and commercializes therapeutic products for tissue protection healing and repair. The Company’s products are based on hyaluronic acid (HA) a naturally occurring biocompatible polymer found throughout the body. The Company’s wholly owned subsidiary Anika S.r.l. has about 20 products commercialized primarily in Europe. These products are also all made from HA based on two technologies: HYAFF which is a solid form of HA and ACP gel an autocross-linked polymer of HA. The Company’s technologies for modifying the HA molecule allow product properties to be tailored specifically to therapeutic use. The Company offers therapeutic products from these technologies in the areas of: Orthobiologics Dermal (Advanced wound care and Aesthetic dermatology) Surgical (Anti-adhesion and Ear nose and throat care (ENT)) Ophthalmic and Veterinary.